<i>Candida albicans</i>spondylodiscitis

Ugarriza, L F; Cabezudo, J.M.; Lorenzana, Luis; Rodríguez-Sánchez, J.A.

doi:10.1080/02688690410001681091

Cited by 13 publications

(6 citation statements)

References 13 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Laboratory results frequently revealed elevated ESR and CRP, but a normal WBC count, in accordance with our case 5,7) . Although plain radiograph frequently reveals erosive and destructive changes of the vertebral body, MR imaging is the diagnostic tool of choice for Candida spondylodiscitis 10,14) . Williams et al 14) reported different MR imaging features, including absence of disc high signal intensity and preservation of the intranuclear cleft in T2-weighted images in the case of fungal spondylitis.…”

Section: Discussionmentioning

confidence: 99%

Cervical Spondylodiscitis Caused by Candida Albicans in Non-Immunocompromised Patient

Moon

Kim

Moon

et al. 2008

J Korean Neurosurg Soc

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Cervical Spondylodiscitis Caused by Candida Albicans in Non-Immunocompromised Patient

Moon

Kim

Moon

et al. 2008

J Korean Neurosurg Soc

View full text Add to dashboard Cite

“…On the other hand, Candida vertebral osteomyelitis remains a rare condition (11,14,15). The species more frequently involved are C. albicans (62%), C. tropicalis (19%), and C. glabrata (14%).…”

Section: Case Reportmentioning

confidence: 99%

Spondylodiscitis Caused by Candida krusei : Case Report and Susceptibility Patterns

et al. 2006

View full text Add to dashboard Cite

A 62-year-old man with amphotericin B-resistant Candida krusei spondylodiscitis, following an episode of candidemia caused by the same strain, was successfully treated with caspofungin plus voriconazole. Amphotericin B fungicidal concentrations were better predictors of the clinical outcome than were MICs. This is the first case of C. krusei spondylodiscitis reported in the literature. CASE REPORTA 62-year-old man was diagnosed with acute myeloid leukemia (FAB-M2) in May 2002. The treatment consisted of idarubicin plus citarabine (3 ϩ 7 regimen), achieving complete remission. In July 2002, consolidation was given without problems. Three months later, intensification chemotherapy (mitoxantrone plus citarabine) was administered. Oral fluconazole (100 mg daily) was given for antifungal prophylaxis. On day 10 after chemotherapy, during the severe neutropenia period, the patient presented with fever, myalgia, and disseminated painful skin nodules. Several blood cultures were positive for C. krusei, but culture of a specimen obtained by fine-needle aspiration of the skin lesion was negative. At that moment, the cumulative dose of fluconazole was 1,500 mg. Antifungal therapy was started with liposomal amphotericin B (3 mg/kg/day) for 2 weeks in association with standard-dose caspofungin for 4 weeks. Other therapeutic measures included removal of the central venous catheter (the tip culture was negative) and administration of filgrastim until neutropenia recovery. In addition, he received oral itraconazole (200 mg twice a day for 4 weeks) as an outpatient. In January 2003, 4 months after the candidemia episode, he presented with fever and severe dorsal back pain. Physical examination did not reveal any neurological deficit. A computed tomography (CT) scan showed a left paravertebral mass, with soft tissue involvement at the D5-D6 level. The magnetic resonance imaging (MRI) findings were consistent with spondylodiscitis ( Fig. 1), and the culture of a specimen collected by CT-guided fine-needle biopsy yielded C. krusei. Because of the presence of high (Ն 8 mg/liter) amphotericin B minimum fungicidal concentrations (MFCs), a combination of standard doses of caspofungin and voriconazole was administered for 6 weeks, with a favorable clinical response. Posterior voriconazole maintenance therapy was given, and surgical treatment was not required. After a 6-month follow-up, the evolution remained good on the basis of clinical and MRI evidence, but the patient died 2 months later due to a relapse of leukemia.The two C. krusei strains isolated from blood (CK-18) and biopsy (CK-19) specimens were identified by molecular techniques, according to the method of Esteve-Zarzoso et al. (9). Strain characterization was performed by PCR amplification and subsequent restriction analysis of the 5.8S-ITS region. To confirm the correct identification, an amplification of partial 26S rRNA gene sequences was carried out. The results obtained were compared with the database available online at the IATA website (http://motor.edinfo.es/iata/), a...

show abstract

“…The risk factors include illicit intravenous drug abuse, alcoholism, diabetes, central venous catheters, parenteral feeding, prolong antibiotic use, and post-spinal surgery. [2,3] In the present case, our patient had two risk factors, i.e. chronic alcoholism and central venous catheterization.…”

mentioning

confidence: 70%

Candida albicans spondylodiscitis in an immunocompetent patient

Joshi

2012

Journal of Neurosciences in Rural Practice

View full text Add to dashboard Cite

Candida albicansspondylodiscitis

Cited by 13 publications

References 13 publications

Cervical Spondylodiscitis Caused by Candida Albicans in Non-Immunocompromised Patient

Cervical Spondylodiscitis Caused by Candida Albicans in Non-Immunocompromised Patient

Spondylodiscitis Caused by Candida krusei : Case Report and Susceptibility Patterns

Candida albicans spondylodiscitis in an immunocompetent patient

Contact Info

Product

Resources

About